advertisement

11.14 Investigational drugs; pharmacological experiments (2498)

Showing records 1 to 25

Display only abstracts from IGR 7-2 in classification 11.14 Investigational drugs; pharmacological experiments

94608 Recovery of deepening of the upper eyelid sulcus after switching from prostaglandin FP receptor agonists to EP2 receptor agonist: a 3-month prospective analysis
Sakata R
Japanese Journal of Ophthalmology 2021; 65: 591-597 (IGR: 22-2)

94605 A Randomized Phase 2 Trial Comparing Omidenepag Isopropyl 0.002% Once and Twice Daily in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SPECTRUM-6)
Olander KW
Journal of Glaucoma 2021; 30: 473-480 (IGR: 22-2)

94934 Sovesudil (locally acting rho kinase inhibitor) for the treatment of normal-tension glaucoma: the randomized phase II study
Ha A
Acta Ophthalmologica 2022; 100: e470-e477 (IGR: 22-2)

94982 Ripasudil Endgame: Role of Rho-Kinase Inhibitor as a Last-Ditch-Stand Towards Maximally Tolerated Medical Therapy to a Patient of Advanced Glaucoma
Naik M
Clinical Ophthalmology 2021; 15: 2683-2692 (IGR: 22-2)

94608 Recovery of deepening of the upper eyelid sulcus after switching from prostaglandin FP receptor agonists to EP2 receptor agonist: a 3-month prospective analysis
Fujishiro T
Japanese Journal of Ophthalmology 2021; 65: 591-597 (IGR: 22-2)

94934 Sovesudil (locally acting rho kinase inhibitor) for the treatment of normal-tension glaucoma: the randomized phase II study
Kim YK
Acta Ophthalmologica 2022; 100: e470-e477 (IGR: 22-2)

94982 Ripasudil Endgame: Role of Rho-Kinase Inhibitor as a Last-Ditch-Stand Towards Maximally Tolerated Medical Therapy to a Patient of Advanced Glaucoma
Kapur M
Clinical Ophthalmology 2021; 15: 2683-2692 (IGR: 22-2)

94605 A Randomized Phase 2 Trial Comparing Omidenepag Isopropyl 0.002% Once and Twice Daily in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SPECTRUM-6)
Sato MA
Journal of Glaucoma 2021; 30: 473-480 (IGR: 22-2)

94934 Sovesudil (locally acting rho kinase inhibitor) for the treatment of normal-tension glaucoma: the randomized phase II study
Jeoung JW
Acta Ophthalmologica 2022; 100: e470-e477 (IGR: 22-2)

94982 Ripasudil Endgame: Role of Rho-Kinase Inhibitor as a Last-Ditch-Stand Towards Maximally Tolerated Medical Therapy to a Patient of Advanced Glaucoma
Gupta V
Clinical Ophthalmology 2021; 15: 2683-2692 (IGR: 22-2)

94608 Recovery of deepening of the upper eyelid sulcus after switching from prostaglandin FP receptor agonists to EP2 receptor agonist: a 3-month prospective analysis
Saito H
Japanese Journal of Ophthalmology 2021; 65: 591-597 (IGR: 22-2)

94605 A Randomized Phase 2 Trial Comparing Omidenepag Isopropyl 0.002% Once and Twice Daily in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SPECTRUM-6)
Abrams MA; Jerkins GW
Journal of Glaucoma 2021; 30: 473-480 (IGR: 22-2)

94982 Ripasudil Endgame: Role of Rho-Kinase Inhibitor as a Last-Ditch-Stand Towards Maximally Tolerated Medical Therapy to a Patient of Advanced Glaucoma
Sethi H
Clinical Ophthalmology 2021; 15: 2683-2692 (IGR: 22-2)

94608 Recovery of deepening of the upper eyelid sulcus after switching from prostaglandin FP receptor agonists to EP2 receptor agonist: a 3-month prospective analysis
Nakamura N
Japanese Journal of Ophthalmology 2021; 65: 591-597 (IGR: 22-2)

94934 Sovesudil (locally acting rho kinase inhibitor) for the treatment of normal-tension glaucoma: the randomized phase II study
Satyal S
Acta Ophthalmologica 2022; 100: e470-e477 (IGR: 22-2)

94982 Ripasudil Endgame: Role of Rho-Kinase Inhibitor as a Last-Ditch-Stand Towards Maximally Tolerated Medical Therapy to a Patient of Advanced Glaucoma
Srivastava K
Clinical Ophthalmology 2021; 15: 2683-2692 (IGR: 22-2)

94605 A Randomized Phase 2 Trial Comparing Omidenepag Isopropyl 0.002% Once and Twice Daily in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SPECTRUM-6)
Lu F
Journal of Glaucoma 2021; 30: 473-480 (IGR: 22-2)

94934 Sovesudil (locally acting rho kinase inhibitor) for the treatment of normal-tension glaucoma: the randomized phase II study
Kim J
Acta Ophthalmologica 2022; 100: e470-e477 (IGR: 22-2)

94608 Recovery of deepening of the upper eyelid sulcus after switching from prostaglandin FP receptor agonists to EP2 receptor agonist: a 3-month prospective analysis
Honjo M; Shirato S
Japanese Journal of Ophthalmology 2021; 65: 591-597 (IGR: 22-2)

94605 A Randomized Phase 2 Trial Comparing Omidenepag Isopropyl 0.002% Once and Twice Daily in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SPECTRUM-6)
Dinh P
Journal of Glaucoma 2021; 30: 473-480 (IGR: 22-2)

94934 Sovesudil (locally acting rho kinase inhibitor) for the treatment of normal-tension glaucoma: the randomized phase II study
Kim S
Acta Ophthalmologica 2022; 100: e470-e477 (IGR: 22-2)

94608 Recovery of deepening of the upper eyelid sulcus after switching from prostaglandin FP receptor agonists to EP2 receptor agonist: a 3-month prospective analysis
Miyamoto E
Japanese Journal of Ophthalmology 2021; 65: 591-597 (IGR: 22-2)

94934 Sovesudil (locally acting rho kinase inhibitor) for the treatment of normal-tension glaucoma: the randomized phase II study
Park KH
Acta Ophthalmologica 2022; 100: e470-e477 (IGR: 22-2)

94605 A Randomized Phase 2 Trial Comparing Omidenepag Isopropyl 0.002% Once and Twice Daily in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SPECTRUM-6)
Odani-Kawabata N; Chabi A
Journal of Glaucoma 2021; 30: 473-480 (IGR: 22-2)

94608 Recovery of deepening of the upper eyelid sulcus after switching from prostaglandin FP receptor agonists to EP2 receptor agonist: a 3-month prospective analysis
Yamada Y
Japanese Journal of Ophthalmology 2021; 65: 591-597 (IGR: 22-2)

• «
• 1
• 2
• 3
• 4
• 5
• »